Article thumbnail

Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma

By Salvia Jain, Catherine Diefenbach, Jasmine Zain and Owen A O’Connor

Abstract

Proteasome inhibition forms the cornerstone of antimyeloma therapy. The first-in-class proteasome inhibitor, bortezomib, either alone or in combination with other chemotherapeutic agents, induces high overall response rates and response qualities in patients with clinically and molecularly defined high-risk disease. However, resistance to bortezomib and neurotoxicity associated with the treatment remain challenging issues. Carfilzomib is a novel, well tolerated, irreversible proteasome inhibitor with minimal neurotoxicity. Carfilzomib demonstrates promising activity in myeloma patients who are refractory to bortezomib and immunomodulatory agents. This review focuses on the pharmacology, safety, and efficacy of carfilzomib for the treatment of multiple myeloma in bortezomib-naïve and bortezomib-exposed populations

Topics: Review
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3102580
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A Phase 2 study of bortezomib in relapsed, refractory myeloma.
  2. A Phase 3 prospective randomized international study (MMY-3021) comparing subcutaneous and intravenous administration of bortezomib in patients with relapsed multiple myeloma.
  3. (2009). A Phase I dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res.
  4. A Phase I–II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma.
  5. (2007). A Phase II study of bortezomib in mantle cell lymphoma: The National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol.
  6. A randomized Phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
  7. Alkaline phosphatase variation during carfilzomib treatment is associated to best response in multiple myeloma.
  8. and dexamethasone in patients with relapsed or relapsed/ refractory multiple myeloma (MM): Encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a Phase II study.
  9. Anti-tumor activity of PR-171, a novel irreversible inhibitor of the proteosome. Cancer Res.
  10. (1999). Antitumor activity of thalidomide in refractory multiple myeloma.
  11. (2005). Biochemical and cellular characterization of the novel proteasome inhibitor PR-171. Blood.
  12. Bortezomib in combination with bendamustine and prednisone in the treatment of patients with refractory/relapsed multiple myeloma.
  13. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.
  14. Bortezomib or highdose dexamethasone for relapsed multiple myeloma.
  15. Bortezomib resistant cell lines have increased proteasome levels but remain sensitive to carfilzomib.
  16. Bortezomib therapy in patients with relapsed or refractory lymphoma: Potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.
  17. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.
  18. Carfilzomib in combination with Dex and other agents (Dox, thal, DDP, vorinostat ) for far advanced and refractory multiple myeloma (FARMM). J Clin Oncol.
  19. Carfilzomib, a novel proteasome inhibitor for relapsed or refractory multiple myeloma, is associated with minimal peripheral neuropathic effects.
  20. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
  21. Clinical efficacy of VEL-CTD (bortezomib, cyclophosphamide, thalidomide, and dexamethasone) regimen in patients with relapsed or refractory multiple myeloma: A Phase II study.
  22. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
  23. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis of α1, β1-epoxyketone proteasome inhibitors.
  24. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of β-lactone ring opening and a mechanism for irreversible binding.
  25. (2008). Development of proteasome inhibitors in oncology and autoimmune diseases. Current Opin Drug Discov Devel.
  26. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.
  27. Dose escalation study of carfilzomib plus lenalidomide plus low-dose dexamethasone in relapsed and refractory MM. J Clin Oncol.
  28. (2007). doxorubicin and dexamethasone (PAD) combination therapy followed by thalidomide and dexamethasone (TD) as a salvage treatment for relapsed multiple myeloma (MM): Preliminary analysis of efficacy and
  29. doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol.
  30. (2005). Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res.
  31. Final results of PX-171-003-A0, part 1 of an open label, single arm, Phase II study of carfilzomib (CFZ) in patients with relapsed and refractory multiple myeloma. J Clin Oncol.
  32. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.
  33. Improved survival in multiple myeloma and the impact of novel therapies.
  34. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): An analysis of the Greek Myeloma Study Group (GMSG).
  35. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
  36. Influence of cytogenetics in patients with relapsed and refractory multiple myeloma treated with carfilzomib.
  37. Inhibition of the proteasome in bone marrow derived CD138+ tumor cells following carfilzomib administration in relapsed and refractory myeloma patients.
  38. low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma.
  39. (2008). Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat.
  40. melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
  41. Molecular basis of bortezomib resistance: Proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
  42. Multicenter Phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.
  43. Neurotoxic and peripheral neuropathic beffects in preclinical and clinical studies of carfilzomib, a novel proteasome inhibitor. J Clin Oncol.
  44. (2008). Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line. Exp Hematol.
  45. pharmacodynamics and anti-tumor efficacy of PR-171, a novel inhibitor of the 20S proteasome.
  46. (2009). Phase 1 clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma
  47. Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma.
  48. Phase I single agent antitumor activity of twice weekly consecutive dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies.
  49. Phase I study of carfilzomib in patients with relapsed and refractory multiple myeloma and varying degrees of renal insufficiency.
  50. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma.
  51. (2009). Phase II results of Study PX-171-007: A Phase Ib/II study of carfilzomib, a selective proteasome inhibitor, in patients with selected advanced metastatic solid tumors. J Clin Oncol.
  52. Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
  53. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
  54. (2008). Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/ leukemia line. J Pharmacol Exp Ther.
  55. Potent activity of carfilzomib, a novel irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
  56. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. Bioorg Med Chem Lett.
  57. (2008). Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res.
  58. (2008). Proteasome β subunit pharmacogenomics: Gene resequencing and functional genomics. Clin Cancer Res.
  59. PX-171-004, a multicenter Phase II study of carfilzomib in patients with relapsed myeloma: An efficacy update. J Clin Oncol.
  60. PX-171-004, an ongoing open label Phase II study of single agent carfilzomib in patients with relapsed or refractory MM; updated results from the bortezomib treated cohort.
  61. PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low-dose dexamethasone in relapsed and refractory MM: Preliminary results. J Clin Oncol.
  62. Results of an ongoing open label, Phase II study of carfilzomib in patients with relapsed and/or refractory MM. J Clin Oncol.
  63. Results of PX-171-003-A1, an open label, single arm, Phase 2 study of carfilzomib in patients with relapsed and refractory multiple myeloma.
  64. Targeted inhibition of the proteasome is a potent strategy against models of myeloma that overcome resistance to conventional drugs and nonspecific proteasome inhibitors.
  65. Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
  66. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.
  67. The effect of bortezomib monotherapy and bortezomib-based regimens on bone metabolism in patients with relapsed/refractory multiple myeloma. Paper presented at:
  68. (2003). The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in
  69. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs.
  70. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukemia cells.
  71. (2004). The proteasome: A suitable antineoplastic target. Nat Rev Cancer.
  72. (2003). The proteasome: Structure, function, and role in the cell. Cancer Treat Rev.
  73. (2008). The reduced intensity CVD regimen: A good option with well-balanced efficacy/toxicity ratio for elderly patients with poor status performance.
  74. Treatment with histone deacetylase-6 inhibitor WT-161 disrupts hsp-90 function, abrogates aggresome formation and sensitizes human mantle cell lymphoma cells to lethal ER stress induced by proteasome inhibitor carfilzomib.
  75. (2010). Updated results of a Phase Ib/II study of carfilzomib in patients with relapsed malignancies. J Clin Oncol.
  76. (2009). Updated results of bortezomibnaïve patients in PX-171-004, an ongoing open label, Phase II study of single agent carfilzomib in patients with relapsed or refractory
  77. VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma.